BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 17538975)

  • 1. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy.
    Krishnan S; Rana V; Janjan NA; Varadhachary GR; Abbruzzese JL; Das P; Delclos ME; Gould MS; Evans DB; Wolff RA; Crane CH
    Cancer; 2007 Jul; 110(1):47-55. PubMed ID: 17538975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer.
    Esnaola NF; Chaudhary UB; O'Brien P; Garrett-Mayer E; Camp ER; Thomas MB; Cole DJ; Montero AJ; Hoffman BJ; Romagnuolo J; Orwat KP; Marshall DT
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):837-44. PubMed ID: 24606850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer.
    Faisal F; Tsai HL; Blackford A; Olino K; Xia C; De Jesus-Acosta A; Le DT; Cosgrove D; Azad N; Rasheed Z; Diaz LA; Donehower R; Laheru D; Hruban RH; Fishman EK; Edil BH; Schulick R; Wolfgang C; Herman J; Zheng L
    Am J Clin Oncol; 2016 Feb; 39(1):18-26. PubMed ID: 24351782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411.
    Crane CH; Winter K; Regine WF; Safran H; Rich TA; Curran W; Wolff RA; Willett CG
    J Clin Oncol; 2009 Sep; 27(25):4096-102. PubMed ID: 19636002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation.
    Krishnan S; Rana V; Janjan NA; Abbruzzese JL; Gould MS; Das P; Delclos ME; Palla S; Guha S; Varadhachary G; Evans DB; Wolff RA; Crane CH
    Cancer; 2006 Dec; 107(11):2589-96. PubMed ID: 17083124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoradiotherapy with or without induction chemotherapy for locally advanced pancreatic cancer: a UK multi-institutional experience.
    Gillmore R; Laurence V; Raouf S; Tobias J; Blackman G; Meyer T; Goodchild K; Collis C; Bridgewater J
    Clin Oncol (R Coll Radiol); 2010 Sep; 22(7):564-9. PubMed ID: 20605709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience.
    Leone F; Gatti M; Massucco P; Colombi F; Sperti E; Campanella D; Regge D; Gabriele P; Capussotti L; Aglietta M
    Cancer; 2013 Jan; 119(2):277-84. PubMed ID: 22778019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction chemotherapy followed by chemoradiation in locally advanced pancreatic cancer: an effective and well-tolerated treatment.
    Hudson E; Hurt C; Mort D; Brewster AE; Iqbal N; Joseph G; Crosby TD; Mukherjee S
    Clin Oncol (R Coll Radiol); 2010 Feb; 22(1):27-35. PubMed ID: 19896352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer.
    Kim JS; Lim JH; Kim JH; Im SA; Chie EK; Hwang JH; Kim TY; Bang YJ; Ha SW; Yoon YB
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):381-9. PubMed ID: 22806305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?
    Crane CH; Abbruzzese JL; Evans DB; Wolff RA; Ballo MT; Delclos M; Milas L; Mason K; Charnsangavej C; Pisters PW; Lee JE; Lenzi R; Vauthey JN; Wong AB; Phan T; Nguyen Q; Janjan NA
    Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1293-302. PubMed ID: 11955742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of induction chemotherapy with gemcitabine plus 5-fluorouracil followed by gemcitabine-based concurrent chemoradiotherapy for unresectable locally advanced pancreatic cancer.
    Kurt E; Kurt M; Kanat O; Cetintas SK; Aygun S; Palazoglu T; Ozkan L; Evrensel T; Kaya E; Manavoglu O
    Tumori; 2006; 92(6):481-6. PubMed ID: 17260487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer.
    Hurt CN; Falk S; Crosby T; McDonald A; Ray R; Joseph G; Staffurth J; Abrams RA; Griffiths G; Maughan T; Mukherjee S
    Br J Cancer; 2017 May; 116(10):1264-1270. PubMed ID: 28376080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoradiation in patients with isolated recurrent pancreatic cancer - therapeutical efficacy and probability of re-resection.
    Habermehl D; Brecht IC; Bergmann F; Welzel T; Rieken S; Werner J; Schirmacher P; Büchler MW; Debus J; Combs SE
    Radiat Oncol; 2013 Jan; 8():27. PubMed ID: 23369246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes and prognostic factors of stereotactic body radiation therapy combined with gemcitabine plus capecitabine for locally advanced unresectable pancreatic cancer.
    Shen ZT; Zhou H; Li AM; Ji XQ; Jiang CC; Yuan X; Li B; Zhu XX; Huang GC
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):417-428. PubMed ID: 31667573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escalation study.
    Vainshtein JM; Schipper M; Zalupski MM; Lawrence TS; Abrams R; Francis IR; Khan G; Leslie W; Ben-Josef E
    Int J Radiat Oncol Biol Phys; 2013 May; 86(1):96-101. PubMed ID: 23265573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: a Taiwan cooperative oncology group phase II study.
    Ch'ang HJ; Lin YL; Wang HP; Chiu YF; Chang MC; Hsu CH; Tien YW; Chen JS; Hsieh RK; Lin PW; Shan YS; Cheng AL; Chang JY; Whang-Peng J; Hwang TL; Chen LT
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e749-57. PubMed ID: 21420250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Definitive chemoradiation therapy with capecitabine in locally advanced pancreatic cancer.
    Kim HS; Yi SY; Jun HJ; Lee J; Park SH; Lee JK; Lee KT; Lee KH; Choi DW; Choi SH; Heo JS; Park YS; Lim HY; Kang WK; Park HC; Lim DH; Park JO
    Anticancer Drugs; 2010 Jan; 21(1):107-12. PubMed ID: 19829097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCD/SFRO phase III trial].
    Barhoumi M; Mornex F; Bonnetain F; Rougier P; Mariette C; Bouché O; Bosset JF; Aparicio T; Mineur L; Azzedine A; Hammel P; Butel J; Stremsdoerfer N; Maingon P; Bedenne L; Chauffert B
    Cancer Radiother; 2011 Jun; 15(3):182-91. PubMed ID: 21315644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent chemoradiotherapy with or without induction chemotherapy versus chemotherapy alone in patients with locally advanced pancreatic cancer.
    Huang WK; Kuo YC; Tsang NM; Hsu HC; Shen WC; Chou WC; Yang TS; Chen JS
    Anticancer Res; 2014 Nov; 34(11):6755-61. PubMed ID: 25368287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer.
    Arvold ND; Ryan DP; Niemierko A; Blaszkowsky LS; Kwak EL; Wo JY; Allen JN; Clark JW; Wadlow RC; Zhu AX; Fernandez-Del Castillo C; Hong TS
    Cancer; 2012 Jun; 118(12):3026-35. PubMed ID: 22020923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.